Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

  • Kappos L
  • Bates D
  • Edan G
 et al. 
  • 22


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Natalizumab, a highly specific alpha4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.

Author-supplied keywords

  • *Patient Selection
  • Animals
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal/adverse effects/*therapeuti
  • Drug Monitoring/methods/*standards
  • Humans
  • Integrin alpha4beta1/antagonists & inhibitors
  • Leukoencephalopathy, Progressive Multifocal/chemic
  • Multiple Sclerosis, Relapsing-Remitting/*drug ther
  • Practice Guidelines as Topic/*standards
  • Treatment Outcome

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • L Kappos

  • D Bates

  • G Edan

  • M Eraksoy

  • A Garcia-Merino

  • N Grigoriadis

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free